Growth-Factor Nanocapsules That Enable Tunable Controlled Release for Bone Regeneration.

Growth factors are of great potential in regenerative medicine. However, their clinical applications are largely limited by the short in vivo half-lives and the narrow therapeutic window. Thus, a robust controlled release system remains an unmet medical need for growth-factor-based therapies. In this research, a nanoscale controlled release system (degradable protein nanocapsule) is established via in situ polymerization on growth factor. The release rate can be finely tuned by engineering the surface polymer composition. Improved therapeutic outcomes can be achieved with growth factor nanocapsules, as illustrated in spinal cord fusion mediated by bone morphogenetic protein-2 nanocapsules.

[1]  Munish C. Gupta,et al.  The Effects of BMP-7 in a Rat Posterolateral Intertransverse Process Fusion Model , 2003, Journal of spinal disorders & techniques.

[2]  Daniel Scherman,et al.  Growth factor delivery approaches in hydrogels. , 2009, Biomacromolecules.

[3]  Francesca Ungaro,et al.  Controlled drug delivery in tissue engineering. , 2008, Advanced drug delivery reviews.

[4]  Jeffrey C. Wang,et al.  The Adjunctive Effect of a Binding Peptide on Bone Morphogenetic Protein Enhanced Bone Healing in a Rodent Model of Spinal Fusion , 2008, Spine.

[5]  Y. Iwasaki,et al.  Enzyme-degradable phosphorylcholine porous hydrogels cross-linked with polyphosphoesters for cell matrices. , 2007, Biomaterials.

[6]  D. Mooney,et al.  Polymers for pro- and anti-angiogenic therapy. , 2007, Biomaterials.

[7]  Tabata,et al.  The importance of drug delivery systems in tissue engineering. , 2000, Pharmaceutical science & technology today.

[8]  David E. Golan,et al.  Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.

[9]  Suzanne Zeitouni,et al.  Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy , 2010, Proceedings of the National Academy of Sciences.

[10]  Mikaël M. Martino,et al.  Extracellular matrix-inspired growth factor delivery systems for bone regeneration. , 2015, Advanced drug delivery reviews.

[11]  R. Langer,et al.  Tissue engineering: current state and perspectives , 2004, Applied Microbiology and Biotechnology.

[12]  Jennifer L. West,et al.  Tethered-TGF-β increases extracellular matrix production of vascular smooth muscle cells , 2001 .

[13]  J. McCarthy,et al.  Exaggerated Inflammatory Response After Use of Recombinant Bone Morphogenetic Protein in Recurrent Unicameral Bone Cysts , 2010, Journal of pediatric orthopedics.

[14]  Yasuhiko Tabata,et al.  Collagenous matrices as release carriers of exogenous growth factors. , 2004, Biomaterials.

[15]  Jeffrey C. Wang,et al.  Inflammatory Characteristics of rhBMP-2 In Vitro and in an In Vivo Rodent Model , 2011, Spine.

[16]  Anthony Guiseppi-Elie,et al.  Bioresponsive Hydrogels , 2013, Advanced healthcare materials.

[17]  Benjamin M Wu,et al.  High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. , 2011, Tissue engineering. Part A.

[18]  Zhen Gu,et al.  A novel intracellular protein delivery platform based on single-protein nanocapsules. , 2010, Nature nanotechnology.

[19]  Hyun Chul Lee,et al.  Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue , 2009, Nature.

[20]  Jeffrey C. Wang,et al.  The Effect of Corticosteroid Administration on Soft-Tissue Inflammation Associated With rhBMP-2 Use in a Rodent Model of Inflammation , 2013, Spine.

[21]  David J Mooney,et al.  Temporally regulated delivery of VEGF in vitro and in vivo. , 2006, Journal of biomedical materials research. Part A.

[22]  S. Werner,et al.  Regulation of wound healing by growth factors and cytokines. , 2003, Physiological reviews.

[23]  B. Henrissat,et al.  The Three-dimensional Structure of Invertase (β-Fructosidase) from Thermotoga maritima Reveals a Bimodular Arrangement and an Evolutionary Relationship between Retaining and Inverting Glycosidases* , 2004, Journal of Biological Chemistry.

[24]  T. Einhorn,et al.  Bone morphogenetic proteins in orthopaedic surgery. , 2009, Cytokine & growth factor reviews.

[25]  S. Namdari,et al.  Recombinant bone morphogenic protein-2 in orthopaedic surgery: a review , 2009, Archives of Orthopaedic and Trauma Surgery.

[26]  Thomas A. Einhorn,et al.  Current and future clinical applications of bone morphogenetic proteins in orthopaedic trauma surgery , 2007, International Orthopaedics.

[27]  Joseph D. Smucker,et al.  Increased Swelling Complications Associated With Off-Label Usage of rhBMP-2 in the Anterior Cervical Spine , 2006, Spine.

[28]  S. Glassman,et al.  Adverse Effects Associated With High-Dose Recombinant Human Bone Morphogenetic Protein-2 Use in Anterior Cervical Spine Fusion , 2006, Spine.

[29]  Cindi M Morshead,et al.  Bioengineered sequential growth factor delivery stimulates brain tissue regeneration after stroke. , 2013, Journal of Controlled Release.

[30]  Dong-Woo Cho,et al.  In vitro and in vivo evaluation of bone formation using solid freeform fabrication-based bone morphogenic protein-2 releasing PCL/PLGA scaffolds , 2014, Biomedical materials.

[31]  M. Mcguire,et al.  Mineralization and pH relationships in healing skeletal defects grafted with demineralized bone matrix. , 1994, Journal of biomedical materials research.

[32]  Kwideok Park,et al.  Controlled release of bone morphogenetic protein (BMP)-2 from nanocomplex incorporated on hydroxyapatite-formed titanium surface. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[33]  J. Feijen,et al.  Release of model proteins and basic fibroblast growth factor from in situ forming degradable dextran hydrogels. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[34]  Z. Fuks,et al.  Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? , 1991, Trends in biochemical sciences.

[35]  J. Tessmar,et al.  Matrices and scaffolds for protein delivery in tissue engineering. , 2007, Advanced drug delivery reviews.

[36]  V. Paralkar,et al.  Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Yang Liu,et al.  Biomimetic enzyme nanocomplexes and their use as antidotes and preventive measures for alcohol intoxication. , 2013, Nature nanotechnology.

[38]  Yang Sun,et al.  Release and bioactivity of bone morphogenetic protein-2 are affected by scaffold binding techniques in vitro and in vivo. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[39]  David J. Mooney,et al.  Controlled Drug Delivery from Polymers by Mechanical Signals , 2001 .

[40]  小倩,et al.  Fusion Rings for Degenerate Minimal Models , 2002 .

[41]  S. Kato,et al.  [Molecular mechanism of switching adipocyte / osteoblast differentiation through regulation of PPAR-gamma function]. , 2008, Clinical calcium.

[42]  D. Mooney,et al.  Polymeric system for dual growth factor delivery , 2001, Nature Biotechnology.

[43]  P. Hammond,et al.  Ordered and kinetically discrete sequential protein release from biodegradable thin films. , 2014, Angewandte Chemie.

[44]  M. Urist,et al.  Human fibrin is a physiologic delivery system for bone morphogenetic protein. , 1988, Clinical orthopaedics and related research.

[45]  S. Carmichael,et al.  Enzyme‐Responsive Delivery of Multiple Proteins with Spatiotemporal Control , 2015, Advanced materials.

[46]  Tatiana Segura,et al.  Controlled Protein Delivery Based on Enzyme‐Responsive Nanocapsules , 2011, Advanced materials.